cerivastatin

Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure.

Examples include cholesterol drugs cerivastatin (Baycol) and simvastatin (Zocor).

Few examples are benoxaprofen, cerivastatin, cisapride, domperidone (injectable), valdecoxib, and sibutramine.

Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.

The studies which were included in this meta-analysis should meet the following criteria: (1) the design of studies should be controlled strictly, including case-control studies, cohort studies, and RCTs; (2) no prior diagnosis of any cancer prior to the date of cancer diagnosis; (3) studies should specific one or more types of statins, including rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, and lovastatin; (4) studies should be designed to evaluate the impact of statins on the risk of cancers with T2DM; (5) studies should have provided sufficient information to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

A retrospective review of the FDA Adverse Event Reporting System (AERS) database found that 88% of fibrate and statin combinations that resulted in rhabdomyolysis were associated with gemfibrozil/cerivastatin (cerivastatin is no longer available in the United States).

Cerivastatin was previously one of the most commonly implicated statin [4,11].

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30.

Several medicines were withdrawn from the market due to their interaction with other substances (mainly related to the CYPs) for example: Seldane[R] (Terfenadine, Aventis Pharmaceuticals, USA), Posicor[R] (Mibefradil, Roche, Switzerland), Propulsid[R] (Cisapride, Janssen-Ortho, Canada), Lotronex[R] (Alosetron, Prometheus Laboratories Inc., USA), Baycol[R] (Cerivastatin, Bayer A.G., Germany) and Serzone[R] (Nefazodone, Bristol-Myers Squibb, USA) (25).